Lexaria Bioscience Corp Ordinary Shares LEXX 深 沪
已收盘 10-24 16:00:00 美东时间
0.9286
+0.019
+2.04%
华盛通- 最 高0.95
- 今 开0.9282
- 成交量 11.83万股
- 最 低 0.9012
- 昨 收 0.91
- 总市值 1816.27万
- 52周最高 2.8499
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 0.7749
- 委 比 91.36%
- 总股本 1955.92万
- 历史最高 12.50
- 量 比 0.55
- 振 幅 5.36%
- 历史最低 0.6488
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience Expands Strategic Outreach and Secures New Patents
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience Corp. h...
10-09 23:08
Lexaria Awarded 4 New Patents Covering Therapeutics For Diabetes, Hypertension, Seizure Disorders, And Antiviral Treatments
Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intellectual property portfolio. These patents support the immense value of our strategic R&D
10-09 21:23
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
09-27 01:05
加拿大药企Lexaria Bioscience早盘重挫27.4%
加拿大药企Lexaria Bioscience(LEXX)早盘下跌27.4%，此前该公司宣布终止与JonesTrading的500万美元股票销售协议。这一决定反...
09-26 23:03
Lexaria Bioscience announces ~$4M registered direct offering of shares
Lexaria Bioscience (NASDAQ:LEXX) was trading lower after the drug delivery platform announced a sale of 2,666,667 shares, par value $0.001 per share, at $1.50 per share in a registered direct offering...
09-26 20:18
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading
Lexaria Bioscience (NASDAQ:LEXX) rose 32% in premarket trading on Friday after the company announced the termination of its Capital on-Demand Sales Agreement with JonesTrading Institutional Services L...
09-26 17:30
Why Are Lexaria Bioscience Shares Soaring 45% After Hours?
Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a dramatic 45.10% surge in after-hours trading on Thursday, climbing to $2.22 from its closing price of $1.53.
09-26 12:00
Lexaria Bioscience Ends Capital on Demand Agreement
An announcement from Lexaria Bioscience ( ($LEXX) ) is now available. On Septem...
09-26 05:49
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
<p>Lexicon Pharmaceuticals has submitted additional clinical data from third-party funded trials to address the FDA's December 2024 complete response letter regarding Zynquista (sotagliflozin), an SGLT1/SGLT2 inhibitor for treating type 1 diabetes. The FDA has delayed its feedback to the fourth quarter, originally expected by September, following discussions about potential regulatory paths forward for the drug's resubmission. Lexicon requested a...
09-22 20:00
Lexaria Bioscience Announces Results From Fluorescently Tagged Semaglutide Rodent Biodistribution Study
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery
09-19 23:22
